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Abstract
Sirtuin 3, an NAD+-dependent deacetylase, whose expression is considered a marker in
life extension, is downregulated with age and in various diseases. Sirtuin 3 is predomi-
nantly localized to the mitochondria and considered a fidelity protein for the integrity and
function of this organelle. Some studies report its localization in the nucleus to regulate
the expression of stress response–related genes and that reduced expression of SIRT3
produces a cellular milieu permissive for human pathologies. Since the expression and
activity of Sirtuin 3 are important for the regulation of antioxidant defense, metabolism,
and apoptosis initiation, the expression of SIRT3 is also important in the context of age-
associated illnesses. A variety of small molecules are being developed to modulate the
expression or activity of Sirtuin 3 and are potentially a valuable strategy to change
mitochondrial acetylome to treat several diseases. The AMPK-PGC1α-SIRT3 axis plays a
critical role in preserving mitochondrial biogenesis and function. Here, we summarize
how changes in Sirtuin 3 expression are regulated in cancer and dysfunctions in cardio-
vascular diseases. The potential therapeutic strategies by targeting Sirtuin 3 expression to
improve mitochondrial function in cancer and cardiovascular diseases are summarized.
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1. Introduction
With the identification of sirtuins (SIRTs), acetylation/deacetylation of proteins has become
evident as an essential and highly regulated posttranslational modification, especially for the
majority of mitochondrial proteins [1]. Acetylation can regulate the activity of an enzyme,
stability or subcellular localization of a protein, transcriptional activity, and DNA-protein
interactions. Silent information regulator 2 (Sir2) is the founding member of sirtuins, which
was characterized in yeast, Saccharomyces cerevisiae. Sir2 functions in silencing gene expression
by histone deacetylation [2]. It has been proposed that overexpression of Sir2 leads to an
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increase in life expectancy in yeast and other model organisms, such as Caenorhabditis elegans
and Drosophila [3]. In these model organisms, the activity of Sir2 is stimulated by multiple
physiological events and stress signals, including starvation, calorie restriction, osmotic stress,
and heat shock [4, 5].
SIRT histone deacetylases differ from traditional class I and II histone deacetylases (HDACs) in
two ways: first, the substrates of SIRTs are not limited to histones and they can target key
enzymes or proteins in the cytoplasm and mitochondria in addition to histones in the nucleus
[6]. Second, SIRTs require nicotinamide adenine dinucleotide (NAD+) for their enzymatic
activity. Their dependence on NAD+ is important for the regulation of metabolism and links
the activity of SIRTs to the energy status of the cells. This is important for a cell to respond to
different stress factors with a suitable stress response to sustain homeostasis. For example, in
starvation, calorie restriction, exercise, or a cellular genotoxicity, increased cellular NAD+ levels
can activate SIRTs. Like Sir2, activated and/or upregulated SIRTs deacetylate their numerous
targets to create a proper cellular stress response.
In mammals, seven SIRT isoforms have been identified, which can be found in different
subcellular compartments. SIRT1, SIRT6, and SIRT7 are localized to the nucleus; SIRT3, SIRT4,
and SIRT5 are localized mainly in the mitochondria; and SIRT2 is mostly present in the
cytoplasm, but it might translocate into the nucleus [7]. Mammalian SIRTs have been proposed
to have numerous beneficial effects, such as increasing insulin secretion, ATP synthesis, and
lipid mobilization; however, the mechanism of how these beneficial effects translate into life
span extension is poorly understood. SIRT3 gene expression has been observed to be
upregulated with high frequency in long-lived individuals [8, 9]. In these individuals, muta-
tions in an enhancer region of the SIRT3 gene are believed to upregulate its expression, and
high SIRT3 expression can be considered a marker for longevity.
Calorie restriction is defined as lowering dietary calorie intake without malnutrition and has
been described to extend the life span of many organisms from yeast to mammals and decrease
the occurrence of age-related diseases, such as cancer, cardiovascular diseases, neurodegener-
ative diseases, and diabetes [10, 11]. In both yeast and C. elegans, caloric restriction–induced
longevity is reliant on the existence of Sir2 [4]. Parallel to studies on Sir2, subsequent studies
suggested that beneficial effects of calorie restriction might be associated with the upregulation
of SIRT expression. SIRT3 transcription was stimulated in hepatocytes and skeletal muscle of
mice on calorie restricted–diet, while a long-term high-fat diet resulted in lowering SIRT3
expression and increasing mitochondrial protein acetylation [12, 13]. SIRT3 expression
declines in individuals over 59 years of age [14, 15], which may contribute to the increased
incidence of cardiovascular diseases and cancer in aging population. Studying SIRT3 in these
diseases may provide important mechanistic connection between the mitochondrial function
and age-associated disorders [16–20]. SIRT3 expression is important for mitochondrial biogen-
esis, regulation of metabolism, ATP synthesis, suppression of reactive oxygen species (ROS),
stress responses, and cell signaling [15, 19, 21–23].
Investigators report that SIRT3 regulates the activity of the transcription factors, Forkhead box
O 3a (FOXO3a), and nuclear factor κB (NF-κB) [24, 25]; however, regulation of SIRT3 tran-
scription itself is not completely understood up-to-date. SIRT3 gene is located in a bidirectional
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arrangement with another gene, called PSMD13, in a phylogenetically conserved manner. The
promoter of the two genes is separated by a 788-bp intergenic region. SIRT3 holds a rich GC
content but lacks a TATA box. Human SIRT3 promoter has binding sites for activator protein
(AP-1), NF-κB, ZF5 transcription factor, GATAs, and specificity protein 1 (SP1) [26]. There is
evidence that peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α)
upregulates SIRT3 transcription, conveyed by an estrogen-related receptor (ERR)-binding
element in the promoter of SIRT3 in mouse muscle cells and hepatocytes [27]. PGC-1α and
ERRα display a synergic action on SIRT3 promoter activity [27]. Furthermore, SIRT3 increases
PGC1-α gene expression by activating AMPK signaling pathway and provides a positive
feedback loop. Activation of AMPK signaling pathway leads to phosphorylation of cAMP
response element-binding protein (CREB), which directly activates the PGC1-α promoter [28].
The positive feedback loop between SIRT3 and PGC1-α is important for mitochondrial biogen-
esis and activation of enzymes associated with the antioxidant system and regulation of
metabolism [6, 27, 28]. In another study, bioinformatics analysis has been revealed that tran-
scription factor binding motifs might be present in SIRT3 promoter. Nuclear respiratory factor
2 (NRF-2) transcription factor regulates mitochondrial genes, including antioxidant enzymes.
NRF-2 has been reported to directly bind to the SIRT3 promoter and increase the expression of
SIRT3 mRNA during nutrient stress [29].
2. Changes in Sirtuin 3 expression in carcinogenesis
Acetylation/deacetylation of specific lysine amino acids of proteins is a prevalent regulatory
mechanism responsible for modulating signaling pathways, survival, apoptosis, and energy
metabolism that takes part in important roles in cellular transformation [30]. SIRTs regulate
various cellular activities, such as gene silencing, cellular proliferation, survival, apoptosis,
stress response, and energy generation by protein deacetylation [31, 32].
SIRT3 is mostly localized in the mitochondria, and it deacetylates many critical metabolism-
related proteins; decreases the levels of mitochondrial ROS; and ultimately regulates prolifera-
tion, differentiation, and survival in response to a stress stimulus [20, 33]. SIRT3 is considered a
fidelity protein because it plays important roles in integrity and maintenance of mitochondrial
function [6, 34, 35]. SIRT3 expression has been determined to be the highest in the heart, liver,
brain, and brown adipose tissue where metabolic activity is relatively high [36]. Genetic deletion
of SIRT3 in mouse has been reported not to produce any significant phenotypic abnormalities
when the mouse is younger than 1 year old. SIRT3 knockout mice are viable, fertile, and
metabolically active when these animals are still young. The difference between SIRT3-deficient
mice andwild-type animals is that knockout mice express increased numbers of hyperacetylated
proteins in their mitochondria, suggesting SIRT3 is the primary deacetylase in this organelle [37].
In normal conditions, SIRT3 gene deficiency does not produce any abnormalities; however, a
different picture emerges when SIRT3 knockout mice get older than 12 months or encounter a
stress stimulus. These mice might be prone to tumor formation, especially in the breast [38].
SIRT3-deficientmice older than 1year olddevelopwell-differentiated estrogen- andprogesterone-
positivemammary tumors [38]. This subtype ofmammary tumors ismore commonly observed in
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women over 60 years old. In human estrogen- and progesterone-positive mammary tumor sam-
ples, SIRT3 expression is found to be reduced compared to noncancerous breast tissues [38]. The
SIRT3 knockout mouse is suggested to be a convenient model to study this subtype of breast
tumors. Additional studies on SIRT3-deficient mice revealed that ionizing radiation causes
vacuolization in SIRT3 knockout mouse hepatocytes, suggesting SIRT3 protects hepatocytes
against ionizing radiation–induced damage [38]. Moreover, SIRT3-deficient mice may develop
age-related hearing loss [19]. SIRT3 expression is reduced in various tumors, and at least one allele
of SIRT3 gene is deleted in about 40% of breast and ovarian tumors and 20% of all human
cancer samples [38, 39]. SIRT3 expression is associated closely with cancer because it has essential
regulatory roles inmitochondrial ROS scavenging,ATP synthesis,metabolism, andmitochondrial
function [38].
Electron transport chain in mitochondria is the main source of the generation of ROS, such as
superoxide. ROS homeostasis is strictly regulated in the cell, and while ROS play a part as
secondary messengers at normal conditions, excessive ROS can damage cellular biomolecules
and contribute to mitochondrial dysfunction and carcinogenesis [40]. SIRT3 has been shown to
directly deacetylate and stimulate manganese superoxide dismutase (MnSOD) activity, which
is the principle ROS scavenger in the mitochondria [20]. In addition, SIRT3 could induce
expression of MnSOD, catalase, and isocitrate dehydrogenase (IDH2) by deacetylating
FOXO3a transcription factor, triggering its translocation into the nucleus and transcription of
these antioxidant enzymes [20, 25, 41, 42].
In the majority of tumors, pyruvate is preferentially transformed into lactate even in the exis-
tence of adequate oxygen. In this process, termed the Warburg effect, metabolism shifts in favor
of glycolysis to increase the raw materials necessary for making new cancer cells [30, 43, 44]. In
other words, glycolytic rate is increased in cancer cells. SIRT3 has been revealed to bring about
degradation of HIF-1α, which results in suppression of the expression genes involved in glycol-
ysis and angiogenesis [45]. SIRT3 displays this action indirectly through reductions in ROS level,
which activates oxygen-dependent prolyl hydroxylases (PHD). In this regard, profilin1 (Pfn1)
has been reported to have an anticancer feature in pancreatic cancer by upregulating SIRT3,
which in turn results in degradation of HIF-1α and reduction in the expression of glycolytic
genes [46]. Furthermore, SIRT3 has a second action to stimulate mitochondrial respiration by
directly targeting electron transport chain and some metabolic enzymes, such as pyruvate
dehydrogenase complex, and induce higher ATP production [22, 47–49].
Since SIRT3 takes part in mitochondrial ROS scavenging, regulation of metabolism, and
mitochondrial function, it is not surprising that reduced expression of SIRT3 is highly associ-
ated with carcinogenesis [6, 30]. In addition, reduced SIRT3 expression is suggested to be a
biomarker for breast cancer associated with poor prognosis [50, 51]. In addition to breast
cancer, SIRT3 might play tumor suppressive roles in pancreatic cancer [52], hepatocellular
carcinoma [53, 54], B cell lymphoma cells [55], and metastatic ovarian cancer [56]. In addition,
kaempferol, a flavonoid, increases SIRT3 expression and its mitochondrial import; hence, it
stimulates apoptosis in leukemia cell lines [57].
SIRT3 has also been reported to take part in an oncogenic function by promoting cancer
initiation or progression depending on the tissue of origin and intracellular signal pathways
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[30]. Oncogenic properties of SIRT3 are attributed to its actions in stimulation of proliferation,
resistance to oxidative stress, and suppression of apoptosis. SIRT3 could play an oncogenic
role in a spectrum of cancers including oral squamous cell carcinoma [58], breast cancer [59],
esophageal cancer [60], gastric cancer [61], colorectal cancer [62], and melanoma cell lines [63].
SIRT3 is predominantly located in the mitochondria; however, there are studies reporting its
localization in the nucleus and having a function in regulating gene expression response to
stress factors [64, 65]. We have previously shown that the loss of expression of SIRT3 in mouse
liver and cultured mouse embryonic fibroblasts results in a cellular environment susceptible to
carcinogenesis and cellular transformation [38, 66]. In the subsequent study, we investigated
how SIRT3 alters the gene expression of cancer-related pathways in SIRT3 wild-type and
SIRT3 knockout mouse hepatocytes. We studied how deficiency of SIRT3 expression might
change the gene expression profile of various transcription factors and proteins linked to
tumor formation in addition to genes associated with metabolism using a commercially avail-
able real-time polymerase chain reaction kit that screens gene expression profiling of diverse
pathways [66]. We found upregulated expression of several genes having oncogenic properties
including cyclin-dependent kinase inhibitor 1A P21 (Cdkn1a), myelocytomatosis oncogene
(Myc), and nitric oxide synthase (NOS2) in SIRT3-deficient mouse liver. These genes are often
overexpressed in human cancers, primarily in breast tumors. In contrast, several genes that
were previously reported to be downregulated in human breast cancer containing B-cell
translocation gene 2 (BTG2), early growth response 1 (EGR1), and Gadd4 had decreased
expression with larger than 2-folds in the SIRT3-deficient hepatocytes [66]. The list of genes
with larger than 2-folds in the cancer-associated pathways and genes associated with insulin-
lipoprotein-cholesterol metabolism is presented in Figure 1.
3. Protective effects of SIRT3 in stress responses in the heart and changes
in SIRT3 expression in cardiovascular diseases
The heart produces and uses more than 90% of its ATP frommitochondrial aerobic respiration in
the cardiomyocytes, which have one of the highest mitochondrial density among all mammalian
cells [67]. Mitochondria are critical in regulating oxidative stress signaling during cardiovascular
Figure 1. Changes in the expression of p53, signal transduction pathway, and insulin-lipoprotein-cholesterol genes in
SIRT3-deficient livers compared to SIRT3 wild-type mouse based on [66].
Changes in the Expression and the Role of Sirtuin 3 in Cancer Cells and in Cardiovascular Health and Disease
http://dx.doi.org/10.5772/intechopen.71865
167
physiology and pathology by regulating cell death, ROS homeostasis, and ATP levels in
cardiomyocytes. Heart failure might be caused by the imbalance in cardiac metabolism, oxida-
tive stress, and opening of the mitochondrial permeability transition pore, which are important
cellular contributors to myocardial ischemia/reperfusion (IR) injury and the development of
cardiac hypertrophy [68–70]. Recent evidence demonstrated that the mitochondrial NAD+-
dependent enzyme, SIRT3, may regulate critical intracellular processes, such as oxidative stress,
cell survival, and cellular metabolism for a healthy cardiac function [71].
In mammals, SIRT3 is one of seven NAD+-dependent protein deacetylases or ADP-
ribosyltransferases that regulates mitochondrial enzyme activity important in maintaining the
integrity of the mitochondria and having a cardioprotective role [17, 72, 73]. Lanza et al. found
that SIRT3 expression is downregulated with age, especially pronounced after 60 years old,
and chronic endurance training causes elevation of SIRT3 expression along with beneficial
health effects and potential lifespan-extending properties [74]. SIRT3, whose expression is rich
in the heart, is the main deacetylase in the mitochondria and its absence produces hyperace-
tylation of numerous proteins in this organelle [75]. Increased acetylation of mitochondrial
proteins, such as cyclophilin D, an important regulator of the permeability transition pore
(mPTP), in the heart in response to IR injury has been reported [69, 76].
The changes in expression of SIRT3 are appealing to the study of cardiovascular diseases
because of its presence mainly in the mitochondria, where a large part of the reactive oxygen
species (ROS) is generated in the cardiomyocytes [77]. Overproduction of ROS in mitochondria
has been linked to the development of cardiac hypertrophy [71]. High levels of cellular ROS
damage biomolecules and accelerate the death of cardiomyocytes via apoptosis and necrosis
[78–81]. Increased ROS was measured in cardiomyocytes isolated from hearts with hypertro-
phy induced by α-adrenergic agonists, namely angiotensin II, endothelin 1, norepinephrine,
tumor necrosis factor, or cyclic mechanical stretch. Furthermore, induced hypertrophy could
be repressed by the application of antioxidants [82–84]. ROS generation has been shown to
activate diverse hypertrophic signal transduction pathways, including NF-κB, mitogen-activated
protein kinase (MAPK), and protein kinase C (PKC) to stimulate hypertrophy [85–87]. SIRT3
mediates the mitochondrial ROS levels by inducing transcriptional expression of mitochondrial
antioxidant enzymes by deacetylating FOXO3a transcription factor and its translocation into the
nucleus [42]. In other words, SIRT3 has been well shown to participate in preventing hypertro-
phy by restricting ROS through activating MnSOD and catalase.
SIRT3 knockout mice are born without any significant abnormalities in their hearts; however,
as they become 2 months of age, they display some indications of cardiac hypertrophic
response and interstitial fibrosis, suggesting a protective role of SIRT3 against cardiac hyper-
trophy [42]. SIRT3 gene–removed mice have been reported to develop an accelerated age-
related weakening in cardiac contractile function, which is characterized as an increase in
end-diastolic volume, and are more prone to transaortic constriction-induced left ventricular
hypertrophy [68, 88]. SIRT3 gene–removed mice can also display spontaneous pulmonary
hypertension and have reduced oxygen consumption rate in their pulmonary artery smooth
muscle cells [89]. In those knockout cells, the investigators pointed out that the expression of
HIF1α, STAT3, and NFATc2 transcription factors increased, which might be responsible for the
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development of this disease [89]. Knockdown of SIRT3 expression increases the vulnerability
of both H9c2 cardiomyocytes and Langendorff preparations to simulate IR injury [18]. More-
over, IR injury is more pronounced in the aged hearts where SIRT3 expression is reduced,
suggesting SIRT3 deficiency contributes to age-related loss of resistance to IR injury [18].
Consistently, exposure of SIRT3-deficient mouse hearts to global IR using a Langendorff-mode
perfusion leads to significantly reduced postischemic recovery of cardiac function relative to
wild-type mouse hearts due to both elevated mitochondrial ROS production and protein
oxidation [90]. Expression of SIRT3 is upregulated in response to stress and its overexpression
has a protective role for cardiomyocytes from stress-mediated cell death by deacetylating Ku70
and preventing translocation of BAX to mitochondria [91]. Additionally, SIRT3 overexpression
protects cardiomyocytes from oxidative stress by downregulating apoptosis regulator BAX
and BCL-2 by inducing NF-κB transcription factor [24].
SIRT3 also has crucial roles in regulating metabolism of cardiovascular cells. SIRT3 improves
mitochondrial oxidative phosphorylation for the production of ATP [47]. SIRT3 also regulates
lipid metabolism by directly activating long-chain acyl CoA dehydrogenase (LCAD) enzyme
activity, which diminishes lipid accumulation–induced cardiac hypertrophy [92]. In this
regard, SIRT3 expression is downregulated in mice fed with high-fat diet; correspondingly,
SIRT3 gene–removed mouse heart displays more noticeable hypertrophy [93]. Heart isolated
from SIRT3-deficient mice shows impaired mitochondrial and cardiac contractile function
accompanied by increased glycolysis and decreased palmitate oxidation and oxygen con-
sumption [88]. Additionally, in SIRT3-deficient heart cells, 84 hyperacetylated mitochondrial
proteins including enzymes for fatty acid metabolism, several subunits of electron transport
chain, and enzymes involved in the Krebs cycle have been identified, proposing the impor-
tance of SIRT3 in maintaining a stable myocardial energy status [88].
Exogenous SIRT3 expression decreases mitochondrial ROS production and improves respi-
ratory capacity in vitro [94, 95]. In recent years, increasing numbers of pharmacological
agents to stimulate the expression or activity of SIRT3 to support a healthy cardiac function
have been reported. Resveratrol, which is a general SIRT activator, is proposed to have a
cardioprotective effect by decreasing the levels of mitochondrial ROS through upregulation
of SIRT3 expression [96]. Resveratrol activates AMPK-PGC-1α, which activates the binding
of ERRα to the SIRT3 promoter and increases SIRT3 mRNA transcription. Increased SIRT3
expression in the mitochondria in turn increases the deacetylation and activation of antioxi-
dant enzymes, primarily MnSOD, and stimulates ATP synthesis to contribute to reduction in
oxidative injury in endothelial cells [96]. In a recent study, it has been reported that adjudin,
which is a lonidamine analog, upregulated the expression of SIRT3 and consequently
protected cells against oxidative damage by eliminating ROS [97]. This agent might also
have a cardioprotective potential.
In addition to resveratrol, other agents use the same signaling pathway to support cardiopro-
tection. Melatonin has been reported to have an important cardioprotective action, which also
uses AMPK-PGC-1α-SIRT3 signaling pathway. The investigators of the study reported that the
protective effect of melatonin on diabetic myocardial IR injury is prevented by silencing SIRT3
expression [98].
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Honokiol, which is a polyphenol derived from magnolia tree, lessens cardiac hypertrophy and
fibrosis by activating SIRT3 and protects cardiomyocytes from doxorubicin-induced cell
destruction and death by promoting mitochondrial fusion and limiting mitochondrial ROS
levels and mtDNA damage [99, 100]. Adenovirus-mediated overexpression of SIRT3 might
decrease pathogenesis of cardiovascular diseases by inhibition of Dox-induced cardiac hyper-
trophy and mitochondrial defects. Overexpression of the transcriptional cofactor receptor-
interacting protein 140 (RIP140) increased cardiomyocyte hypertrophy and decreased ATP
production along with mitochondrial dysfunction by decreasing the expression of SIRT3 in
neonatal rat cardiomyocytes [101]. Repression of SIRT3 expression by RIP140 is dependent on
ERRα [101]. A hexokinase inhibitor, 2-deoxy-d-glucose, administration significantly improves
cardiac function and reduces myocardial apoptosis [102]. Zhen et al. pointed out that
upregulation of SIRT3 expression along with SIRT1 by this agent might be important contrib-
utors to its protective action against septic cardiomyopathy [102]. Stimulation of SIRT3 expres-
sion improves the mitochondrial respiratory function and improves the cardiac function of
mice. Metformin, which is a drug used for the treatment of diabetes, upregulates the expres-
sion of SIRT3 in about 8 weeks old mice with heart failure after myocardial infarction [103]. It
was suggested that metformin-mediated SIRT3 upregulation and deacetylation of PGC-1α
increase mitochondrial ATP production and mitochondrial oxygen consumption rates in the
SIRT3 stimulating
potential
cardioprotective agents
Upstream
signaling of
SIRT3
Direct or indirect SIRT3
substrates and targets
Potential effects of agents in
cardiovascular system and
cardiomyocytes
Associated
references
Resveratrol AMPK, PGC-
1α, and
ERRα
MnSOD, IDH2, GSH-Px,
FOXO3a
Scavenges mtROS [96]
Melatonin AMPK and
PGC1α
MnSOD, NRF1, TFAM,
cytochrome c
Scavenges mtROS, stimulates
mitochondrial biogenesis, and
reduces apoptosis
[98]
Honokiol N/A MnSOD, OGG1, MFN1,
OPA1, Ku70, BCL-2, BAX,
NF-κB
Scavenges mtROS, reduces
apoptosis, and enhances
mitochondrial fusion
[24, 91, 100]
2-deoxy-d-glucose N/A BAX, BAK Reduces apoptosis [24, 102]
Metformin N/A PGC-1α Stimulates mitochondrial ATP
production and oxygen
consumption rates
[103]
Adjudin N/A IDH2 Scavenges mtROS [96, 97]
RIP140 (SIRT3
repressing TF)
ERRα LCAD Increases mtROS and lipid
accumulation
[92, 101]
MnSOD: manganese superoxide dismutase; IDH2: isocitrate dehydrogenase; Forkhead box O 3a (FOXO3a); LCAD: long-
chain acyl-CoA dehydrogenase; AMPK: AMP-activated protein kinase; GSH-Px: glutathione peroxidase; PGC-1α: perox-
isome proliferator-activated receptor gamma coactivator 1-alpha; ERRα: estrogen-related receptor alpha; NRF1: nuclear
respiratory factor 1; TFAM: transcription factor A, mitochondrial; OGG1: 8-oxoguanine glycosylase; MFN-1: mitofusin-1;
OPA1: dynamin-like 120 kDa protein; Ku70; ATP-dependent DNA helicase II, 70 kDa subunit; BCL-2: B-cell lymphoma 2;
NF-κB: nuclear factor kappa-light-chain enhancer of activated B cells; TF: transcription factor.
Table 1. Various agents to stimulate the expression of SIRT3 and the cardioprotective actions of SIRT3.
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mouse hearts of myocardial infarction and decrease the associated damage [103]. A summary
of agents to stimulate the expression of SIRT3 to support a healthy cardiac function and the
possible targets of SIRT3 is presented in Table 1.
4. Conclusions
Cardiovascular diseases and cancer are most common causes of age-associated death around
the world. SIRT3 has been shown to have essential roles in aging, longevity, and stress
response since reduced expression or loss of function of SIRT3 brings about an intracellular
milieu permissive for age-related illnesses. The mechanisms of how SIRT3 protects cells
against cancer formation or cardiovascular diseases are not well understood because of the
fact that SIRT3 has several targets or interacting partners in diverse pathways. Beneficial
possessions of SIRT3 on cancer and particularly on various cardiovascular diseases have been
reported; however, translating the modulation of SIRT3 expression using small molecules for
clinical benefit is in its initial stages. Identification of agents to target SIRT3 expression to
improve mitochondrial function will harvest new therapeutic strategies in the treatment of
cancer and cardiovascular diseases.
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